Filters: Author is Di Monte, D A [Clear All Filters]
Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience. 2005;132(2):409-20.
Woulfe JM, Duke R, Middeldorp JM, Stevens S, Vervoort M, Hashimoto M, et al. Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology. 2002;58(9):1435-6.
Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol. 2001;50(2):254-7.
Thiffault C, Langston JW, Di Monte DA. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 2000;885(2):283-8.
He L, Di Monte DA, Langston JW, Quik M. Autoradiographic analysis of dopamine receptor-stimulated [(35)S]GTPgammaS binding in rat striatum. Brain Res. 2000;885(1):133-6.
Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology. 2000;54(7):1498-504.
Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol. 2000;47(4 Suppl 1):S79-89.
Royland JE, Delfani K, Langston JW, Janson AM, Di Monte DA. 7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced ATP loss in the mouse striatum. Brain Res. 1999;839(1):41-8.
Di Monte DA, Tokar I, Langston JW. Impaired glutamate clearance as a consequence of energy failure caused by MPP(+) in astrocytic cultures. Toxicol Appl Pharmacol. 1999;158(3):296-302.
Langston JW, Sastry S, Chan P, Forno LS, Bolin LM, Di Monte DA. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp Neurol. 1998;154(2):684-90.
Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology. 1998;50(4):1136-7.
Di Monte DA, Royland JE, Anderson A, Castagnoli K, Castagnoli N, Langston JW. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem. 1997;69(4):1771-3.
Irwin I, Delanney L, Chan P, Sandy MS, Di Monte DA, Langston JW. Nigrostriatal monoamine oxidase A and B in aging squirrel monkeys and C57BL/6 mice. Neurobiol Aging. 1997;18(2):235-41.
Chan P, Di Monte DA, Langston JW, Janson AM. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J Pharmacol Exp Ther. 1997;280(1):439-46.
Di Monte DA, Delanney LE, Irwin I, Royland JE, Chan P, Jakowec MW, et al. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res. 1996;738(1):53-9.
Sandy MS, Armstrong M, Tanner CM, Daly AK, Di Monte DA, Langston JW, et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology. 1996;47(1):225-30.
Di Monte DA, Royland JE, Irwin I, Langston JW. Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology. 1996;17(3-4):697-703.
Chan P, Di Monte DA, Langston JW. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brain. Brain Res. 1994;647(2):249-54.

]